Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.
Durect (DRRX) Upgraded to Strong Buy: Here's Why
Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Durect (DRRX) Upgraded to Buy: Here's What You Should Know
Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings!
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago.
DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladies and gentlemen, welcome to the DURECT Corporation Second Quarter 2024 Earnings Conference Call.
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
Are Medical Stocks Lagging DURECT (DRRX) This Year?
Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.
